KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accounts Payables (2016 - 2025)

Jazz Pharmaceuticals has reported Accounts Payables over the past 16 years, most recently at $122.1 million for Q4 2025.

  • Quarterly results put Accounts Payables at $122.1 million for Q4 2025, up 56.75% from a year ago — trailing twelve months through Dec 2025 was $122.1 million (up 56.75% YoY), and the annual figure for FY2025 was $122.1 million, up 56.75%.
  • Accounts Payables for Q4 2025 was $122.1 million at Jazz Pharmaceuticals, down from $152.2 million in the prior quarter.
  • Over the last five years, Accounts Payables for JAZZ hit a ceiling of $152.2 million in Q3 2025 and a floor of $63.8 million in Q3 2021.
  • Median Accounts Payables over the past 5 years was $93.3 million (2022), compared with a mean of $94.2 million.
  • Biggest five-year swings in Accounts Payables: soared 272.23% in 2021 and later plummeted 35.45% in 2024.
  • Jazz Pharmaceuticals' Accounts Payables stood at $100.3 million in 2021, then dropped by 9.51% to $90.8 million in 2022, then grew by 13.21% to $102.8 million in 2023, then decreased by 24.22% to $77.9 million in 2024, then skyrocketed by 56.75% to $122.1 million in 2025.
  • The last three reported values for Accounts Payables were $122.1 million (Q4 2025), $152.2 million (Q3 2025), and $89.4 million (Q2 2025) per Business Quant data.